Barclays raises target for Alvotech stock to USD 8.00

Published on 10/20/2026 at 22:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays set a USD 8.00 target on September 16, 2026. Alvotech stock costs EUR 4.56 on October 20, 2026; Nasdaq ALVO rose 1.79 percent.

Analyst target and reporting date

Barclays raised its Alvotech target from USD 4.00 to USD 8.00 on September 16, 2026.
Alvotech reported Q2 2026 revenue of USD 106.00 million against USD 103.00 million consensus.
Alvotech stock stood at EUR 4.56 at Lang & Schwarz on October 20, 2026 at 10:14 p.m. CEST.
Alvotech is scheduled to report third-quarter 2026 results on November 11, 2026.

Alvotech, LU2458332611, Illustration mit AI erstellt.

Barclays raised its Alvotech target from USD 4.00 to USD 8.00 in a research report dated September 16, 2026, according to MarketBeat. Against the Nasdaq quote of USD 5.12 on October 20, 2026, the USD 8.00 target stands 56.25 percent above the stock price. Alvotech stood at EUR 4.56 at Lang & Schwarz on October 20, 2026 at 10:14 p.m. CEST.

Revenue beat, wider adjusted loss

Alvotech reported USD 106.00 million of revenue for the second quarter of 2026, above the USD 103.00 million consensus estimate, while its adjusted loss was USD 0.11 per share against an expected USD 0.05 loss. MarketBeat reported the figures after Alvotech's August 20, 2026 results. The comparison leaves revenue ahead of expectations by USD 3.00 million, while the adjusted loss was USD 0.06 per share wider than forecast.

Nasdaq price and range

The Nasdaq quote was USD 5.12 on October 20, 2026 at 4:00 p.m. ET, up 1.79 percent from USD 5.03. Finance data put Alvotech's market capitalization at USD 1.8 billion on October 20, 2026. Its 52-week range was USD 2.94 to USD 8.53, placing the quote USD 3.41 below the high and USD 2.18 above the low.

November reporting date approaches

Alvotech is estimated to report third-quarter 2026 results on November 11, 2026, after the market closes, with a conference call scheduled for November 12, 2026. MarketBeat lists consensus revenue of USD 138.11 million for the quarter, compared with USD 113.95 million in the same quarter of 2025, and consensus adjusted earnings of minus USD 0.0197 per share.

Two milestones in October

On October 14, 2026, Alvotech and Advanz Pharma announced a European regulatory submission for a proposed biosimilar to Eylea 8 mg. The company also announced additional manufacturing progress for SIMLANDI earlier in October, adding operational context ahead of the November results.

Price and investor context

The Nasdaq quote, the analyst target and the next reporting date point to three separate reference points for the stock: current trading, valuation expectations and the next financial update. The most recent reported quarter delivered USD 106.00 million of revenue, but the USD 0.11 adjusted loss per share shows why the upcoming results remain material for the target narrative.

Alvotech stood at EUR 4.56 at Lang & Schwarz on October 20, 2026 at 10:14 p.m. CEST. The Nasdaq quote was USD 5.12 at 4:00 p.m. ET on the same date, up 1.79 percent from USD 5.03.

The further course of trading is shown by the continuously updated real-time quote of Alvotech stock.